Skip to main content
Explore URMC

menu

Study of a new cancer sensitivity test (CANscriptTM) that could help inform physicians in selecting treatments

Research Question:
Are CANscript™ test results helpful in selecting the treatments prescribed and provided?

Basic Study Information

Purpose:
The purpose of this study is to trial the CANscript™ sensitivity test, which is a new and different test developed to indicate the sensitivity of different cancer types to physician-selected therapies (both drugs and/or drug combinations). CANscript™ tests how a patient's specific tumor reacts to the therapies being considered by the treating physician. CANscript™ test results have been shown to closely correspond with actual clinical results, providing physicians with information that may help him/her develop a more personalized cancer treatment and care plan based on the patient's specific condition. The researchers want to see if CANscript™ test results are helpful in selecting the treatments prescribed and provided. There will be about 800 people taking part in this study, across 5 different tumor types. The study is designed to assess the decision impact of the CANscript™ test results in informing physicians in therapy selection.

Location: University of Rochester Medical Center
Study Reference #: IGY017084

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search